Medicyte Signs Development Agreement With Life Technologies
Medicyte recently announced it has signed a licensing agreement for the rights to use Lentiviral vector technology from Life Technologies to develop and market next-generation, cell-based upcyte cell products to the biopharma and academic research markets.
Various data, already presented at academic meetings, indicates that Medicyte’s upcyte hepatocytes combine the benefits of quantity (generation of up to 2000 vials per donor) with the quality of primary hepatocytes. The new generation of upcyte hepatocytes show more comparable results to primary cells in in vitro assays (such as CYP 3A4-Induction, genotoxicity or hepato- and cytotoxicity).
“With the technology we have licensed from Life Technologies, we are capable to bring more predictive, reliable, and standardized cell strains on the market,” said Dr. Joris Braspenning, CEO of Medicyte GmbH.
Medicyte is specialized in the controlled generation and standardization of human primary cell products in virtually unlimited quantities and of highest quality for cell therapy and cell-based R&D. Medicytes proprietary technologies upcyte and vericyte enable to expand in a controlled way human hepatocytes from different donors and other cell types in a standardized procedure, thereby making these cells for the first time commercially available in high numbers and consistent quality. For more information, visit www.medicyte.com.
Total Page Views: 980
